DexCom (NASDAQ:DXCM) Lowered to Hold at BidaskClub

BidaskClub downgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research report report published on Tuesday, BidAskClub reports.

Other analysts have also recently issued research reports about the stock. BMO Capital Markets increased their price objective on shares of DexCom from $180.00 to $190.00 and gave the stock an outperform rating in a report on Tuesday, September 3rd. Bank of America increased their price objective on shares of DexCom from $162.00 to $185.00 and gave the stock a buy rating in a report on Thursday, August 1st. UBS Group increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a neutral rating in a report on Thursday, August 1st. Northland Securities reaffirmed a hold rating and issued a $125.00 price objective on shares of DexCom in a report on Thursday, June 6th. Finally, Canaccord Genuity increased their price objective on shares of DexCom from $160.00 to $185.00 and gave the stock a buy rating in a report on Thursday, August 1st. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $168.44.

DXCM stock opened at $154.40 on Tuesday. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $178.45. The firm’s 50-day simple moving average is $159.48 and its 200 day simple moving average is $139.76. The stock has a market cap of $14.08 billion, a PE ratio of 514.67 and a beta of 0.72.



DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business had revenue of $336.40 million for the quarter, compared to analysts’ expectations of $304.40 million. During the same quarter last year, the company earned ($0.10) EPS. The company’s revenue for the quarter was up 38.7% compared to the same quarter last year. Equities analysts forecast that DexCom will post 0.94 EPS for the current fiscal year.

In other DexCom news, EVP Richard Doubleday sold 2,016 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $175.14, for a total transaction of $353,082.24. Following the transaction, the executive vice president now owns 72,570 shares of the company’s stock, valued at approximately $12,709,909.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nicholas Augustinos sold 1,208 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $145.49, for a total transaction of $175,751.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,081 shares of company stock worth $14,300,370. 1.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in DXCM. Price T Rowe Associates Inc. MD increased its stake in DexCom by 359.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock valued at $817,652,000 after buying an additional 4,268,926 shares during the period. Nuveen Asset Management LLC increased its stake in DexCom by 1,781.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock valued at $165,983,000 after buying an additional 1,048,855 shares during the period. Jennison Associates LLC increased its stake in DexCom by 211.2% during the 2nd quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock valued at $208,574,000 after buying an additional 944,642 shares during the period. Artisan Partners Limited Partnership increased its stake in DexCom by 71.6% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,164,081 shares of the medical device company’s stock valued at $138,642,000 after buying an additional 485,519 shares during the period. Finally, Geode Capital Management LLC increased its stake in DexCom by 17.2% during the 4th quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock valued at $124,776,000 after buying an additional 152,781 shares during the period. 96.30% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.